<DOC>
	<DOCNO>NCT02682901</DOCNO>
	<brief_summary>The main objective demonstrate effect early dopaminergic activation autonomic nervous system subject newly diagnose vs. establish type 2 diabetes . The primary endpoint effect Bromocriptine QR change autonomic function measure assess sympathetic parasympathetic function use conventional measure autonomic function , include power spectral analysis heart rate well peripheral autonomic function use sudorimetry laser scan peripheral microvascular autonomic control .</brief_summary>
	<brief_title>Bromocriptine-QR Therapy Sympathetic Tone Vascular Biology Type 2 Diabetes Subjects</brief_title>
	<detailed_description>This interventional , twenty-four week , randomize , double blind , placebo-controlled trial bromocriptine QR subject newly diagnose establish type 2 diabetes mellitus ( T2DM ) evaluate effect cardiovascular peripheral autonomic nervous system , well inflammatory marker , leptin/adiponectin system , hormonal level RAS HPA axis , index insulin resistance , measure oxidative nitrosative stress . Forty newly diagnose diabetes subject 40 subject establish diabetes enrol study randomize treatment bromocriptine-QR placebo . Secondary endpoint demonstrate effect dopaminergic activation Bromocriptine-QR regulation Hypothalamic-Pituitary-Axis ( HPA ) axis hormone , plasma level marker inflammation oxidative/nitrosative stress newly diagnose vs. establish type 2 diabetes subject . The study evaluate treatment effect inflammatory marker , Leptin/Adiponectin system , hormonal level rennin-angiotensin system ( RAS ) , aldosterone cortisol . Specifically , follow marker inflammation oxidative/nitrosative stress : 1 ) C reactive protein ( CRP ) , 2 ) interleukin-6 , 12 , 10 , 3 ) tumor necrosis factor ( TNFalpha ) , 4 ) plasminogen activator inhibitor ( PAI1 ) , superoxide dismutase ( SOD ) , Thiobarbituric acid reactive substance ( TBARS ) Asymmetric dimethylarginine ( ADMA ) evaluate . A co-secondary objective study assess impact Bromocriptine-QR v Placebo measure insulin resistance glycemic control ( e.g. , oral glucose tolerance test ( OGTT ) glucose insulin , Matsuda index , Homeostasis Model Assessment-insulin resistance ( HOMA-IR ) , Hemoglobin A1c ( HbA1c ) .</detailed_description>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>Type 2 diabetes subject age 30 80 year age , inclusive , Screening Hemoglobin A1c ( HbA1c ) ≤10.0 % screen Male female ( female child bear age must use definitive contraceptive therapy ) Type 2 Diabetes Mellitus subject stable antidiabetes regimen diet and/or metformin alone therapy metformin plus insulin secretion enhancer ( sulfonylureas , dipeptidyl peptidase 4 ( DPP4 ) Inhibitors , Glucagonlike peptide ( GLP1 ) analog ) therapy 60 day period prior randomization . Subjects diabetes duration ≥ 4 year must use insulin secretion enhancer ( e.g . sulphonylureas ( SU ) , DPP4 , GLP1 analog ) . Subjects must document Cpeptide level ( either fast random ) &gt; 2 ng/ml screen visit . Presence type 1 diabetes mellitus ( define Cpeptide &lt; 1 ng /ml ) Type 2 diabetes mellitus subject insulin . Use prescription sympathomimetics , ergot alkaloid derivative , antimigraine medication , dopamine2 ( D2 ) like receptor antagonist ( e.g . metoclopramide , domperidone ) systemic corticosteroid Uncontrolled hypertension ( systolic BP &gt; 160 diastolic BP &gt; 100 screen ) history orthostatic hypotension History significant gastroparesis Presence diabetic retinopathy severe `` background '' level Presence diabetic nephropathy , renal impairment define blood urea nitrogen ( BUN ) &gt; 40mg/dl serum creatinine &gt; 1.4 mg/dl female take metformin , &gt; 1.5 mg/dl . male take metformin , &gt; 1.6 mg/dl take metformin Presence clinically significant peripheral autonomic neuropathy clearly nondiabetic origin History major macrovascular event myocardial infarction cerebrovascular event stroke within past 6 month . Other exclusion include coronary artery bypass graft coronary angioplasty previous 3 month , unstable angina pectoris ( chest pain rest , worsen chest pain , admission emergency room hospital chest pain ) within previous 3 month , seizure disorder . Active infection ( e.g. , human immunodeficiency virus ( HIV ) , hepatitis ) , history severe infection 30 day prior screen Major surgical operation 30 day prior screen Cancer , nonmelanoma skin nonmetastatic prostate cancer , within past 5 year Uncontrolled untreated hypothyroidism evidence thyroid stimulate hormone ( TSH ) concentration &gt; 4.8 µU/ml Other serious medical condition , opinion investigator , would compromise subject 's participation study , include concurrent illness , diabetes mellitus , control stable therapeutic regimen , condition abnormality ( e.g. , blindness ) might interfere interpretation safety efficacy data , history noncompliance Clinically significant abnormality screen laboratory evaluation , unless approve Sponsor Abnormalities liver function define liver enzymes ( aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , serum glutamicpyruvic transaminase ( SGPT ) , Serum glutamic oxaloacetic transaminase ( SGOT ) great 3 time upper limit normal History New York Heart Association ( NYHA ) Class IIIIV congestive heart failure . Concurrent participation another clinical trial use experimental drug device within 30 day study entry . History alcohol substance abuse dementia Pregnant lactate woman . Women childbearing potential must negative pregnancy test screening . Women become pregnant discontinued study . Known hypersensitivity formulation component Working rotating , vary night shift Use unapproved herbal supplement may associate risk cardiovascular event ( ephedra , yohimbe etc ) Patients start therapy erectile dysfunction drug within 2 week prior screen ; patient may begin treatment erectile dysfunction drug study period ; patient currently take erectile dysfunction drug medical supervision . Donation blood previous 30 day . Blood donation also allow study 30 day completion study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>